¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 1ÀÏÂ÷ : 2021-09-16

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 1ÀÏÂ÷ : 2021-09-16
±³À°ÀÏÀÚ : 2021-09-16
±³À°Àå¼Ò : ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5Ãþ ±×·£µåº¼·ë  
±³À°ÁÖÁ¦ : ´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 1ÀÏÂ÷
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѽɺÎÀüÇÐȸ  
´ã´çÀÚ : ¹éÁöÀº
¿¬¶ôó : 02-3275-5335  
À̸ÞÀÏ : khfs4@khfs.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 2Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 2 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 70,000¿ø      
ºñ°í ±³¼ö: 70,000¿ø, ÀϹÝÀÇ: 30,000¿ø, Àü°øÀÇ, °£È£»ç, 65¼¼ ÀÌ»ó, Çлý, ±âŸ(ÀÌ¿Ü ÀÇ·áÁ¾»çÀÚ): ¹«·á      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-16 ±×·£µåº¼·ë 15:20~15:40 Complex Interplay between HF and Cancer  Javid Moslehi(Vanderbilt Univ. USA) 
±³À°½Ã°£ 09-16 ±×·£µåº¼·ë 15:00~15:20 Risk Stratification and Prevention of Myocardial Dysfunction in Cancer Patients  ±èÀº°æ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 09-16 ±×·£µåº¼·ë 15:40~16:00 Atrial Fibrillation during Chemotherapy: Risk and Benefit of Anticoagulation  È²ÀÎâ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 09-16 ±×·£µåº¼·ë 16:00~16:10 Multiple Myeloma and Cardiac Amyloidosis : Challenges of Management  Thibaud Damy(University Hospital Henri Mondor France) 
Åä·Ð 09-16 ±×·£µåº¼·ë 16:10~16:20 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ09-16 ±×·£µåº¼·ë 16:20~16:30 Short Coffee Break  () 
±³À°½Ã°£ 09-16 ±×·£µåº¼·ë 16:30~16:45 Korean Perspective, Upcoming ESC HF Guidelines  Á¶ÇöÀç(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 09-16 ±×·£µåº¼·ë 16:45~17:00 What's New in HFrEF?  Andrew Coats(HFA of the ESC) 
±³À°½Ã°£ 09-16 ±×·£µåº¼·ë 17:00~17:15 What's New in HFpEF?  Gerasimos Filippatos(HFA of the ESC) 
±³À°½Ã°£ 09-16 ±×·£µåº¼·ë 17:15~17:30 Chronic or Acute HF? Or HF Continum  À¯º´¼ö(¿¬¼¼¿øÁÖÀÇ´ë) 
Åä·Ð 09-16 ±×·£µåº¼·ë 17:30~18:00 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 1ÀÏÂ÷ : 2021-09-16""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 2ÀÏÂ÷ : 2021-09-17
´ÙÀ½±Û º¸°ÇÀÇ·á NGO ÀÇ ¿ªÇÒ°ú ³ª¾Æ°¥ ¹æÇâ, ±×¸®°í Çʿ伺Àº? : 2021-09-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20469 ±¤ÁÖ ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ±¤ÁÖÀü³²Áöȸ Á¦51Â÷ ÇмúÁý´ãȸ : 2024-05-02 0 25 2024-04-29
20468 ºÎ»ê ´ëÇÑÀ忬±¸ÇÐȸ ºÎ¿ï°æÁöȸ Á¤±âÁý´ãȸ : 2024-04-29 0 64 2024-04-29
20467 ¼­¿ï 2024 ´ëÇÑÇ÷¾×ÇÐȸ Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-31 0 101 2024-04-17
20466 °æ±â ¾ÆÁִ뺴¿ø ÀÀ±ÞÀÇÇаú ¼³¸³ 30Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2024-05-30 0 84 2024-04-17
20465 ¼­¿ï Á¦20Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ ÇÁ·Î±×·¥ : 2024-05-26 0 67 2024-04-17
20464 °æ±â 2024³â Á¦86Â÷ ´ëÇÑ»ý½ÄÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-26 0 57 2024-04-17
20463 ¼­¿ï 2024³â ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-05-26 0 83 2024-04-17
20462 ¼­¿ï ´ëÇÑÃæ°ÝÆÄÄ¡·áÇÐȸ 2024 Ãá°è Çмú´ëȸ : 2024-05-26 0 51 2024-04-17
20461 ¼­¿ï Áø´Ü ü°èÀû¹®Çå°íÂû ¿öÅ©¼¥ : 2024-05-25 0 56 2024-04-17
20460 ¼­¿ï ´ëÇѺñ¸¸ÇÐȸ Á¦17ȸ ODOT (One Day Course of Obesity Treatment) : 2024-05-25 0 66 2024-04-17
20459 ¼­¿ï 2024³â Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2024-05-24 0 47 2024-04-17
20458 ¼­¿ï 2024 Á¦12ȸ ´ëÇÑÇ÷¾×ÇÐȸ Ç÷¿ìº´¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-24 0 86 2024-04-17
20457 ¼­¿ï 2024³â ¿µµîÆ÷±¸ÀÇ»çȸ Ãá°è Çмú´ëȸ : 2024-05-21 0 68 2024-04-17
20456 ¼­¿ï 2024³â ´ëÇÑÀÓ»ó°Ç°­ÁõÁøÇÐȸ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-05-19 0 75 2024-04-17
20455 ¼­¿ï Á¦7Â÷ ´ëÇѼö¸éÈ£ÈíÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-19 0 50 2024-04-17
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷